CASE STUDIES
Diabetes Innovation with CTRx™ and Direct-to-Patient Supply
Study: Phase II Diabetes Clinical Trial
Participants: 100 patients
Solution: CTRx™ Solution & Direct-to-Patient (DTP) Supply Within the US
Challenge
In this diabetes clinical trial, many patients faced financial barriers to accessing insulin, a critical component of their treatment and health outcomes. Due to these financial concerns, the trial experienced low enrollment rates, and there were fears of high dropout rates among those who had enrolled and struggled to afford insulin. This posed a significant threat to the trial’s success and timeline.
The Myonex Solution
Myonex deployed CTRx, utilizing the prescription card element of the solution, in the US. To eliminate financial barriers for patients, the CTRx prescription card provided participants with free insulin by directly reimbursing pharmacies paid for by the Sponsor. The participants were able to use their pharmacy of choice within the CTRx network of 70,000+ pharmacies. The diabetic participant population in the study routinely visited their local pharmacist and were able to pick up insulin required in the study at their pharmacy of choice vs. traveling back to the site. This allowed the Sponsor to focus on the trial without worrying about patient retention or compliance issues related to medication access. Sites were also happy with the solution as they were not required to store additional insulin for the Sponsor. The Sponsor created cost efficiency as they did not need to purchase high quantities of insulin at once and allowed patients to access the insulin in a convenient way through their local pharmacy of choice.
The Results:
Rapid increase in enrollment: Once patient financial barriers were removed through the DTP approach, enrollment rates significantly increased. Patients who previously could not afford insulin could now participate fully in the trial.
Enhanced patient experience: Participants no longer had to worry about traveling to clinical sites for regular visits, leading to a more positive experience, reduced patient burden, and fewer participant dropouts.
Operational efficiency: CTRx streamlined medication access and reduced the administrative burden on sites, allowing the sponsor to focus more on trial execution rather than logistics.
Conclusion:
The CTRx solution model eliminated financial barriers and ensured consistent access to life-saving medications. This diabetes trial experienced a significant boost in both enrollment and retention, resulting in a highly successful trial outcome.
